SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020

SMi Group 15 - 16 January 2020, London, UK.
SMi are pleased to present the 12th Annual Pre-Filled Syringes and Injectable Drug Devices conference in London. As Europe's leading Pre-Filled Syringes conference, the 2020 event will assess innovations in device engineering and components, enhancement of human factors, and optimizing packaging and containment.

With the rapid expansion of the PFS market, the regulatory environment is more importance than ever. This year's programme will look at the EU MDR, Article 117 as well as insights into the MDR post-market surveillance requirements; providing a holistic review of the Pre-Filled Syringes industry.

This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior Pre-Filled Syringes Engineers, Device Testing Managers, Heads of Late-Stage Pre-Filled Syringes Development, Head of Medical Affairs, Senior Director - Combination Products & Medical Devices, Global Regulatory Affairs, Quality Assurance Manager Combination Products, Senior Pharmaceutical Assessor and many more.

Benefits of attending

  • Learn about the technological innovations that are revolutionizing the injectable drug delivery space through novel device design
  • Debate how can we prepare for the regulatory impact of Brexit and the EU MDR on devices
  • Hear industry experts uncovering the latest advancements optimizing drug biologics to improve PFS delivery
  • Assess industry case studies exploring how to overcome challenges of extractables and leachables

Chairs for 2019

  • James Mellman, Device Manager, Novartis
  • Anil Busimi, Strategy and Innovation Global Product Manager, SCHOTT

Featured speakers

  • Abha Raveau-Violette, Device Manager, AstraZeneca
  • Amanda Matthews, Senior Director, Pfizer
  • Anil-Kumar Busimi, Strategy and Innovation, Senior Global Product Manager, SCHOTT
  • Benjamin Werner, Scientist, Boehringer Ingelheim Pharma GmbH & Co. KG
  • Cedric Gysel, Healthcare Solutions Manager, Johnson & Johnson
  • Cinzia Rotella, Senior Materials Scientist, Sanofi
  • Clemens Guenther, Director Nonclinical Safety Consumer Care, Bayer
  • Colin Roscoe, Principal Human Factors Scientist, Teva Pharmaceuticals
  • Hiroki Hasegawa, Researcher, Mitsubishi Gas Chemical Company, Inc
  • James Mellman, Device Manager, Novartis A G
  • Kewei Yang, Pharmaceutical Scientist, Roche
  • Khaudeja Bano, Head of Medical Devices, Abbott Molecular Inc
  • Marion Westwood, Pharmaceutical Assessor, Medicines & Healthcare products Regulatory Agency (MHRA)
  • Matthew Nicolas, Investigator, GlaxoSmithKline
  • Nicolas Eon, Senior Global Product Manager, SCHOTT
  • Olaf Lebau, Design Engineer for Medical Devices and Combination Products, Boehringer Ingelheim GmbH
  • Raphael Nudelman, Director of Chemical and Computational Toxicology, Teva Pharmaceuticals
  • Remy Vomscheid, Director, Devices Development & Technologies, IPSEN Pharmsciences
  • Torsten Kneuss, Quality Assurance Manager Combination Products, Bayer Pharma

Plus, pre-conference workshop day will be taking place on 14th January in London:

Workshop A: A Roadmap to Regulation Quality Management Systems and Technical Standards
Workshop B: Testing Requirements of Pre-Filled Syringes led by Horst Koller, CEO, HK Packaging Consulting GmbH
Workshop C: Extractables and Leachables: Considerations for PFS Platforms

For more information and to register, please visit:
http://www.pre-filled-syringes.com/wpnwl

Early-Bird Rates

  • Register by 29th November to save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...

Sanofi and Translate Bio mRNA COVID-19 vaccine can…

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced...